Lymphangioleiomyomatosis, or LAM, is a rare but serious lung disease that may cause severe respiratory symptoms in patients. The often-fatal disease has no cure.
Researchers say the key to learning more about LAM might lie in better understanding how symptoms differ among LAM patients
University of Cincinnati (UC) scientists are conducting a new research study that examines why symptoms of LAM are different in certain subgroups of people with the goal of finding more successful therapies.
LAM occurs when an unusual type of cell begins to grow out of control and spread to restricted areas in the body, including the lungs, kidneys, lymph nodes and vessels.
A team led by Jean Elwing, MD, an assistant professor in UC's pulmonary, critical care and sleep division, is enrolling female LAM patients to see if pulmonary hypertension and pulmonary vascular disease may be contributing to their respiratory symptoms.
Pulmonary hypertension is a blood vessel disorder of the lungs in which pressure in the pulmonary artery, the blood vessel that leads from the heart to the lungs, rises above normal levels.
"We plan to evaluate a group of women with LAM who are experiencing shortness of breath for the presence of pulmonary hypertension," she says. "We will look at participant's medical history, pulmonary function tests, exercise tolerance, echocardiogram results and previous biopsy samples.
"We are hopeful this information will increase our understanding of how LAM can manifest in the patients it affects. In the future, this information may be useful in developing better management strategies for this disease."
Elwing says this study will compare LAM patients who also have pulmonary hypertension with those who do not to differentiate between the groups.
"Some participants will be seen once in clinic and undergo testing with an echocardiogram while participating in this study," she says. "The individuals who have already undergone a clinical pulmonary hypertension evaluation may be able to participate through a review of select medical records and lung biopsy specimens."
Source: University of Cincinnati
Explore further: Transplant drug sirolimus shrinks tumors, improves lung function